Live Attenuated Vaccines Market Research Report Information, By Type (Bacterial, Viral), By Vaccine Development (Tissue Culture, Embryonated Eggs, Live Animals) and End Users (Hospitals, Clinics, Diagnostic Centers, Research Institute, Others) - Forecast till 2032

Table of Contents

1. Report Prologue

2. Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

2.3 Market Structure

2.4. Market Segmentation

3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Threats

4.5 Macroeconomic Indicators

5. Market Factor Analysis

5.1 Value Chain Analysis

5.2 Porters Five Forces

5.3 Demand & Supply: Gap Analysis

5.4 Pricing Analysis

5.5 Investment Opportunity Analysis

5.6 Merger and Acquisition Landscape

5.7 Up-Coming trends in live attenuated vaccines market

5.7.1 Market trends

5.7.2 Technological trends

6. Global Live Attenuated Vaccines Market by Type

6.1 Bacterial

6.1.1 BCG

6.2 Viral

6.2.1 Oral Polio Vaccine (OPV)

6.2.2 Measles

6.2.3 Rota virus

6.2.3 Yellow fewer

6.2.4 Others

7. Global Live Attenuated Vaccines Market by End User

7.1 Hospitals

7.2 Clinics

7.3 Research institutes

7.4 Others

8. Global Live Attenuated Vaccines Market by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 US

8.2.1.2 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 UK

8.3.1.3 France

8.3.1.4 Italy

8.3.1.5 Spain

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Republic of Korea

8.4.5 Australia

8.4.6 Rest of Asia-Pacific

8.5 Middle East & Africa

8.5.1 United Arab Emirates

8.5.2 Saudi Arabia

8.5.3 Oman

8.5.4 Qatar

8.5.5 Kuwait

8.5.6 Rest of Middle East & Africa

9 Competitive Landscape

10 Company Profile

10.1 GlaxoSmithKline, plc.

10.1.1 Overview

10.1.2 Product/Business Segment Overview

10.1.3 Financial Updates

10.1.4 Key Developments

10.2 Merck & Co.

10.2.1 Overview

10.2.2 Product/Business Segment Overview

10.2.3 Financial Updates

10.2.4 Key Developments

10.3 Pfizer, Inc.

10.3.1 Overview

10.3.2 Product/Business Segment Overview

10.3.3 Financial Updates

10.3.4 Key Developments

10.4 Astellas Pharma Inc.

10.4.1 Overview

10.4.2 Product/Business Segment Overview

10.4.3 Financial Updates

10.4.4 Key Development

10.5 Johnson & Johnson

10.5.1 Overview

10.5.2 Product/Business Segment Overview

10.5.3 Financial Updates

10.5.4 Key Developments

10.6 CSL Limited.

10.6.1 Overview

10.6.2 Product/Business Segment Overview

10.6.3 Financial Updates

10.6.4 Key Developments

10.7 Sanofi

10.7.1 Overview

10.7.2 Product/Business Segment Overview

10.7.3 Financial Updates

10.7.4 Key Developments

10.8 Serum Institute of India Pvt. Ltd

10.8.1 Overview

10.8.2 Product/Business Segment Overview

10.8.3 Financial Updates

10.8.4 Key Developments

10.9 Others

11 Conclusion

11.1 Key Findings

11.1.1 From CEO’s Viewpoint

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Prediction of Vaccine Industry

12 Appendix

LIST OF TABLES

Table 1 Vaccine Industry Synopsis, 2020-2027

Table 2 Global Live Attenuated Vaccine Market Estimates & Forecast, 2020-2027, (USD Million)

Table 3 Global Live Attenuated Vaccine Market, by Region, 2020-2027, (USD Million)

Table 4 Global Live Attenuated Vaccine Market, by Type, 2020-2027, (USD Million)

Table 5 Global Live Attenuated Vaccine Market, by End User, 2020-2027, (USD Million)

Table 6 Americas Live Attenuated Vaccine Market, by Type, 2020-2027, (USD Million)

Table 7 Americas Live Attenuated Vaccine Market, by End User, 2020-2027, (USD Million)

Table 8 North America Live Attenuated Vaccine Market, by Type, 2020-2027, (USD Million)

Table 9 North America Live Attenuated Vaccine Market, by End User, 2020-2027, (USD Million)

Table 10 South America Live Attenuated Vaccine Market, by Type, 2020-2027, (USD Million)

Table 11 South America Live Attenuated Vaccine Market, by End User, 2020-2027, (USD Million)

Table 12 Europe Live Attenuated Vaccine Market, by Type, 2020-2027, (USD Million)

Table 13 Europe Live Attenuated Vaccine Market, by End User, 2020-2027, (USD Million)

Table 14 Western Europe Live Attenuated Vaccine Market, by Type, 2020-2027, (USD Million)

Table 15 Western Europe Live Attenuated Vaccine Market, by End User, 2020-2027, (USD Million)

Table 16 Eastern Europe Live Attenuated Vaccine Market, by Type, 2020-2027, (USD Million)

Table 17 Eastern Europe Live Attenuated Vaccine Market, by End User, 2020-2027, (USD Million)

Table 18 Asia Pacific Live Attenuated Vaccine Market, by Type, 2020-2027, (USD Million)

Table 19 Asia Pacific Live Attenuated Vaccine Market, by End User, 2020-2027, (USD Million)

Table 20 Middle East & Africa Live Attenuated Vaccine Market, by Type, 2020-2027, (USD Million)

Table 21 Middle East & Africa Live Attenuated Vaccine Market, by End User, 2020-2027, (USD Million) 

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Live Attenuated Vaccine Market

Figure 3 Segmentation Market Dynamics for Live Attenuated Vaccine Market

Figure 4 Global Live Attenuated Vaccine Market Share, by Type, 2020

Figure 5 Global Live Attenuated Vaccine Market Share, by End User, 2020

Figure 6 Global Live Attenuated Vaccine Market Share, by Region, 2020

Figure 7 Americas Live Attenuated Vaccine Market Share, by Country, 2020

Figure 8 Europe Live Attenuated Vaccine Market Share, by Country, 2020

Figure 9 Asia Pacific Live Attenuated Vaccine Market Share, by Country, 2020

Figure 10 Middle East & Africa Live Attenuated Vaccine Market Share, by Country, 2020

Figure 11 Global Live Attenuated Vaccine Market: Company Share Analysis, 2020 (%)